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Interferon-alpha (IFN-α) is a proinﬂammatory cytokine that is widely used for the treatment
of chronic viral hepatitis and malignancy, because of its immune-activating, antiviral,
and antiproliferative properties. However, long-term IFN-α treatment frequently causes
depression, which limits its clinical utility. The precise molecular and cellular mechanisms
of IFN-α-induced depression are not currently understood. Neural stem cells (NSCs) in
the hippocampus continuously generate new neurons, and some evidence suggests
that decreased neurogenesis plays a role in the neuropathology of depression. We
previously reported that IFN-α treatment suppressed hippocampal neurogenesis and
induced depression-like behaviors via its receptors in the brain in adult mice. However, it
is unclear how systemic IFN-α administration induces IFN-α signaling in the hippocampus.
In this study, we analyzed the role of microglia, immune cells in the brain, in mediating the
IFN-α-induced neurogenic defects and depressive behaviors. In vitro studies demonstrated
that IFN-α treatment induced the secretion of endogenous IFN-α from microglia, which
suppressed NSC proliferation. In vivo treatment of adult mice with IFN-α for 5 weeks
increased the production of proinﬂammatory cytokines, including IFN-α, and reduced
neurogenesis in the hippocampus. Both effectswere prevented by simultaneous treatment
with minocycline, an inhibitor of microglial activation. Furthermore, minocycline treatment
signiﬁcantly suppressed IFN-α-induced depressive behaviors inmice.These results suggest
that microglial activation plays a critical role in the development of IFN-α-induced depres-
sion, and thatminocycline is a promising drug for the treatment of IFN-α-induced depression
in patients, especially those who are low responders to conventional antidepressant
treatments.
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INTRODUCTION
Interferon-alpha is a proinﬂammatory cytokine that is widely
used for the treatment of chronic viral hepatitis and malignancy,
because of its immune-activating, antiviral, and antiprolifera-
tive properties (Tagliaferri et al., 2005; Deutsch and Hadziyannis,
2008; Papatheodoridis et al., 2008). However, the use of IFN-α
can result in the development of various side effects includ-
ing digestive, skin, and neuropsychiatric symptoms (Dieperink
et al., 2000; Malek-Ahmadi, 2001). Depression is the most preva-
lent and severe side effect, affecting approximately 30–45%
of patients receiving IFN-α treatment, thus limiting its clin-
ical utility (Bonaccorso et al., 2001; Lieb et al., 2006). While
numerous studies have suggested the involvement of neuro-
chemical and/or neuroendocrinological pathways in the devel-
opment of IFN-α-induced depression (Schiepers et al., 2005;
Reyes-Vazquez et al., 2012; Hoyo-Becerra et al., 2014), the
Abbreviations: IFN-α, interferon-alpha; NSC, neural stem cell; SGZ, subgranular
zone; DG, dentate gyrus; IFNAR, type 1 interferon receptor; IL, interleukin; TNF,
tumor necrosis factor.
underlying molecular and cellular mechanisms remained to be
clariﬁed.
In the adult mammalian brain, NSCs, which are located in
the SGZ of the DG and in the ventricular–subventricular zone
(V-SVZ) located at the lateral wall of lateral ventricles, gener-
ate new neurons daily throughout life (Altman and Das, 1965;
Doetsch and Alvarez-Buylla, 1996; Jankovski and Sotelo, 1996;
Eriksson et al., 1998; Gould et al., 1999; Petreanu and Alvarez-
Buylla, 2002). Although the functional signiﬁcance of adult-born
neurons is not completely clear, there is growing evidence for their
involvement in mood regulation (Samuels and Hen, 2011; Eisch
and Petrik, 2012). We previously reported, using brain-speciﬁc
IFN receptor knockout mice and hippocampal NSC cultures,
that IFN-α directly suppresses proliferation of the hippocam-
pal and V-SVZ NSCs and the generation of new neurons, and
that it induces depressive behavioral phenotypes via the type
1 IFN receptor (IFNAR), expressed in the central nervous sys-
tem (Kaneko et al., 2006; Zheng et al., 2014). These ﬁndings
suggest that IFN-α may induce depression by directly affect-
ing neural cells in the brain. However, in addition to the small
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fraction of circulating IFN-α passing through the blood–brain
barrier, IFN-α is also produced locally in the brain (Dafny
and Yang, 2005). Therefore, it is still unclear how systemic
IFN-α administration induces IFNAR signaling in NSCs in the
brain.
Inﬂammation has been implicated in the pathophysiology
of depression (Dantzer et al., 2008; Miller et al., 2009). Con-
sistent with this notion, higher levels of proinﬂammatory
cytokines and inﬂammatory markers are found in the periph-
eral blood of depressed individuals, compared to controls (Maes,
1999; Schiepers et al., 2005; Dowlati et al., 2010). In the brain,
the activation of microglia by various inﬂammatory stimuli
(Garden and Moller, 2006; Dheen et al., 2007) leads to the release
of excess proinﬂammatory cytokines, which contribute to the
pathophysiology of neurological and psychiatric disorders, includ-
ing depression (Hanisch and Kettenmann, 2007; Maes, 2011).
Notably, several proinﬂammatory cytokines directly affect NSC
proliferation and neurogenic functions (Das and Basu, 2008;
Gonzalez-Perez et al., 2012), andmicroglial activation inhibits hip-
pocampal neurogenesis (Ekdahl et al., 2003; Monje et al., 2003). In
addition, IFN-α stimulates the production of a series of proin-
ﬂammatory cytokines not only in the periphery, but also within
the central nervous system (Raison et al., 2009; Felger et al., 2013).
On the basis of these studies, we hypothesized that proinﬂam-
matory cytokines secreted by activated microglia are involved in
IFN-α-induced depression.
Here, we found that chronic IFN-α treatment increased the
production of proinﬂammatory cytokines, including endoge-
nous IFN-α, and reduced neurogenesis in the adult mouse
hippocampus, and that simultaneous treatment with minocy-
cline, an inhibitor of microglial activation, prevented these effects.
Furthermore, minocycline treatment signiﬁcantly suppressed
IFN-α-induced depression-like behaviors in mice. These results
suggest that microglial activation mediates the development of
IFN-α-induced depression.
MATERIALS AND METHODS
ANIMALS
Male 8-week-old C57BL/6J mice were purchased from SLC
(Shizuoka, Japan). All experiments using live animals were per-
formed in accordance with the guidelines and regulations of
Nagoya City University.
ADMINISTRATION OF IFN-α, MINOCYCLINE, AND
BROMODEOXYURIDINE
Mice were given daily intraperitoneal (i.p.) injections of either
phosphate-buffered saline (PBS) ormouse IFN-α (Miltenyi Biotec,
Auburn, CA, USA) diluted with PBS at a dose of 4 × 105 IU/kg,
for 4 or 5 weeks; this dosage is reported to induce depression-
like behavioral changes (Zheng et al., 2014). Minocycline (Sigma,
Saint Louis, MO,USA) diluted with PBS was injected i.p. at a dose
of 50 mg/kg (Li et al., 2013) for 2 d prior to and throughout the
IFN-α-treatment period.
To label newly generated cells, at the beginning of the 5th week
of IFN-α treatment, mice were injected with bromodeoxyuridine
(BrdU; Sigma, 50 mg/kg, i.p., in PBS) once every 8 h for a total of
six injections.
CELL CULTURE AND TREATMENTS
The murine microglia cell line BV-2 (Blasi et al., 1990) was
cultured at 37◦C in 5% CO2 in the following maintenance
medium: Dulbecco’s modiﬁed Eagle’s medium/Nutrient mixture
F12 (DMEM/F12, Gibco, Carlsbad, CA, USA), supplemented
with 10% fetal bovine serum (FBS, Gibco) and 1% penicillin–
streptomycin. The cells were plated into 24-well culture plates
(1× 105 cells/well) for ELISA or 100-mmculture dishes (1.2× 106
cells/dish) for collecting conditionedmedia (CM). For preparation
of the CM the BV-2 microglia were treated with IFN-α (1 × 103
IU/ml) or PBS (unstimulated controls) for 6 h, and then incubated
in fresh medium without FBS. CM samples were collected after 6,
12, 18, 24, and 48 h of incubation.
Adult hippocampal NSC cultures were derived from adult
female Fischer 344 rats (Gage et al., 1995) and maintained in
DMEM/F12 medium (Invitrogen, Carlsbad, CA, USA) contain-
ing 1% N2 supplement (Invitrogen) and 20 ng/ml ﬁbroblast
growth factor-2 (FGF-2, PeproTech, Rocky Hill, NJ, USA). The
NSCs were plated into 24-well plates at a density of 3 × 104
cells/well. After 24 h, the microglial CM (collected after 24 h
of incubation), with or without 1 μg/ml anti-IFN-α neutraliz-
ing antibody, (R&D Systems, Piscataway, NJ, USA), was added
to the NSC culture. To label proliferating cells, the NSCs were
treated with 10 μM BrdU (dissolved in cell culture medium)
for the last 4 h of the 48 h incubation period. The results
reported here are based on data obtained from three independent
experiments.
REAL-TIME PCR
To examine the mRNA levels of proinﬂammatory cytokines, mice
were deeply anesthetized, sacriﬁced, and their hippocampal tissues
collected at 2, 6, and 24 h after the ﬁnal injection of IFN-α and/or
minocycline. Total RNA was extracted from the hippocampal tis-
sues with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and
cDNA synthesis was performed using the SuperScript First-Strand
Synthesis System for RT-PCR (Invitrogen). Quantitative SYBR
Green real time PCR was carried out as follows. Brieﬂy, each 25 μl
SYBRGreen reaction consisted of 5μl of cDNA (50 ng/μl), 12.5μl
of 2× Universal SYBR Green PCR Master Mix (Applied Biosys-
tems, Carlsbad, CA, USA), and 3.75 μl each of 50 nM forward
and reverse primers. Optimization was performed for each gene-
speciﬁc primer prior to the experiment, to conﬁrm that the 50 nM
primer concentrations did not produce non-speciﬁc primer-dimer
ampliﬁcation signals in the no-template control tubes. Primer
sequences were designed using Primer Express Software (Applied
Biosystems). Quantitative RT-PCRwas performed on anABI 7500
Fast Real-TimePCR instrument (Applied Biosystems) by using the
following 3-stage program parameters provided by the manufac-
turer: 2 min at 50◦C, 10 min at 95◦C, 40 cycles of 15 s at 95◦C, and
1min at 60◦C. Each sample was tested in duplicate, and the results
obtained from three independent experiments were used to calcu-
late the means and SD. The data are expressed as the fold change
in gene expression relative to the PBS control group. The follow-
ing primers were used: 5′-AAGGACAGGAAGGATTTTGGATT-3′
and 5′-GAGCCTTCTGGATCTGTTGGTT-3′, which amplify a
64-bp IFN-α product; 5′-TTGACGGACCCCAAAAGAT-3′ and
5′-GAAGCTGGATGCTCTCATCAG-3′, which amplify a 75-bp
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IL-1β product; 5′-TGATGGATGCTACCAAACTGGA-3′ and 5′-
TGGTACTCCAGAAGACCAGAGG-3′, which amplify a 75-bp
IL-6 product; 5′-CACAAGATGCTGGGACAGTGA-3′, and 5′-
TCCTTGATGGTGGTGCATGA-3′, which amplify a 58-bp TNF-α
product; and 5′-CATGGCCTTCCGTGTTCCTA-3′ and 5′-
CACGTCAGATCCA-3′, which amplify a 55-bp GAPDH
product.
ELISA ANALYSIS
BV-2 microglia were incubated with IFN-α (103 IU/ml) for 6 h,
washed carefully with PBS to remove IFN-α from the cultures,
and then incubated in the maintenance medium for 6, 12, 18, 24,
or 48 h. The levels of IFN-α, IL-1β, IL-6, and TNF-α released
into the media were measured using ELISA kits (Boster Biologi-
cal Technology, Wuhan, China), according to the manufacturer’s
instructions. The data are presented as fold changes, relative to the
control sample levels.
IMMUNOHISTOCHEMISTRY
Immediately following the treatment period, the mice were
deeply anesthetized and ﬁxed by transcardiac perfusion with
4% paraformaldehyde in 0.1 M phosphate buffer. Brain sections
were prepared and stained as previously described (Kaneko et al.,
2010). Brieﬂy, following post-ﬁxation with 4% paraformalde-
hyde in 0.1 M phosphate buffer overnight, the brains were cut
into 50-μm-thick coronal sections on a vibratome (VT1200S,
Leica,Wetzlar, Germany). The sections were incubated for 40 min
in 1% H2O2 in PBS, 1 h in blocking solution (10% donkey
serum and 0.2% Triton X-100 in PBS), overnight at 4◦C with
the primary antibodies, and 2 h at room temperature with Alexa
Fluor-conjugated secondary antibodies (1:500, Invitrogen). Signal
ampliﬁcation was performed with biotinylated secondary anti-
bodies (1:500, Jackson Laboratory, West Grove, PA, USA) and
the Vectastain Elite ABC kit (Vector Laboratories, Burlingame,
CA, USA), and the signals were visualized using the TSA Fluo-
rescence System (PerkinElmer, Waltham, MA, USA). For BrdU
staining, the sections were pretreated with 2 N HCl for 40 min at
60◦C before H2O2 incubation. The following primary antibod-
ies were used: rat anti-BrdU (1:200, Abcam, Cambridge, MA,
USA); rabbit anti-Iba1 (1:2000, Wako, Osaka, Japan); rabbit
anti-Ki67 (1:500, Leica); rabbit anti-TBR2 (1:200, Abcam); goat
anti-doublecortin (DCX; 1:100, Santa Cruz Biotechnology, Santa
Cruz,CA,USA).Nucleiwere stainedwithHoechst 33342 (1μg/ml,
Sigma).
IMMUNOCYTOCHEMISTRY
As described previously (Palmer et al., 1999), cells on coverslips
were rinsed in PBS and ﬁxed with 4% PFA in 0.1 M phosphate
buffer at room temperature for 15min. After a 1-h pre-incubation
in blocking solution (10% donkey serum and 0.2% Triton X-100
in PBS), the cells were incubated with primary antibodies at 4◦C
overnight, and at room temperature for 2 h with Alexa Fluor-
conjugated secondary antibodies (1:500, Invitrogen). For BrdU
staining, the cells were pretreated with 2 NHCl for 30min at 37◦C
before blocking. The following primary antibodies were used: rat
anti-BrdU (1:1000) and chicken anti-Nestin (1:2000, Aves Labs,
Tigard, OR, USA).
IMAGING QUANTIFICATION
The hippocampal sections were processed and stained as
described above. To visualize and quantify the Ki67- and
TBR2-immunoreactive cells, images of the labeled samples were
captured using a ﬂuorescence microscope (BX-51, Olympus,
Tokyo, Japan) with a 20× objective. To visualize and quantify
BrdU+DCX+ cells, confocal z-stack images with a step size of
1 μm were captured using a confocal laser microscope LSM700
(Carl Zeiss, Jena, TH, Germany) with a 40× objective, and
only the cells with a BrdU+ nucleus completely surrounded
by DCX+ cytoplasm were counted. To visualize and quan-
tify Iba1+ cells, confocal z-stack images with a step of 4 μm
were captured using a confocal laser microscope LSM700 (Carl
Zeiss) with a 20× objective. In all of the histological analyses,
the actual number of cells in every sixth 50-μm-thick coronal
section was counted bilaterally, and the obtained cell num-
ber was multiplied by six to obtain the total number of cells
per DG.
For analysis of the in vitro stimulated cells, the double-labeled
cells were examined with a confocal laser microscope (LSM700,
Carl Zeiss). Three optical ﬁelds were randomly chosen under a
20× objective from each well for quantiﬁcation. The percent-
age of BrdU+ NSCs was calculated by dividing the number of
BrdU+Nestin+ cells by the total number of Nestin+ cells in the
same ﬁeld.
TAIL SUSPENSION TEST
Immediately after the 5-week IFN-α/minocycline treatment, the
mice were subjected to the tail suspension test as described
previously (Steru et al., 1985). Brieﬂy, the mice were sus-
pended 35 cm above the ﬂoor in a visually isolated area by
adhesive tape placed 1–1.5 cm from the tip of the tail. The
escape movement and duration of immobility were recorded
over a 6-min test period. Immobility lasting for less than
2 s was not included in the analysis. The time spent in an
immobile posture was measured as an index of depression-like
behavior.
PORSOLT FORCED SWIM TEST
The Porsolt forced swim test was performed 24 h after the tail
suspension test, as described previously (Porsolt et al., 1977).
Brieﬂy, the mice were placed in a vertical glass cylinder (35 cm
height× 15 cm diameter) ﬁlled with 25 cmwater at 23± 1◦C. The
escape movement and duration of immobility were recorded over
a 6-min test period. Immobility was deﬁned as only those move-
ments required to keep the mouse aﬂoat, and immobility lasting
for less than 2 s was not included in the analysis. The time spent in
an immobile posture was measured as an index of depression-like
behavior.
STATISTICAL ANALYSIS
All data were expressed as the mean ± SEM. Differences
between the means were determined by the two-tailed Stu-
dent’s t-test, one-way ANOVA, or two-way repeated measures
ANOVA, followed by a Tukey–Kramer multiple comparison test,
unless speciﬁed otherwise. A P-value of <0.05 was considered
signiﬁcant.
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RESULTS
MINOCYCLINE ATTENUATES IFN-α-INDUCED PRODUCTION OF
PROINFLAMMATORY CYTOKINES IN THE HIPPOCAMPUS
Previously, we found that mice subjected to peripheral IFN-α
treatment (4 × 105 IU/kg, i.p., once daily for 5 weeks) exhib-
ited suppressed neurogenesis (Zheng et al., 2014). To determine
if peripheral IFN-α treatment leads to hippocampal inﬂamma-
tion, mice were subjected to the same IFN-α treatment regimen,
the hippocampal tissues were collected at 2, 6, and 24 h after
the ﬁnal injection of IFN-α, and the expression of proinﬂam-
matory cytokines was quantiﬁed by real-time PCR (Figure 1A).
IFN-α treatment was previously shown to increase the IL-1β, IL-6,
and TNF-α levels in the brain (Kaneko et al., 2006; Raison et al.,
2009). Consistent with these reports, the mRNA levels of these
cytokines in the hippocampus were signiﬁcantly upregulated by
IFN-α administration, exhibiting ∼2-, 3-, and 8-fold increases
comparedwith the control PBS-treated groupat 6h after treatment
(Figure 1A), suggesting that our treatment protocol efﬁciently
stimulated hippocampal inﬂammation in the mouse. We also
found that our IFN-α treatment protocol increased the IFN-α
mRNA level in the hippocampus, resulting in a greater than
fourfold increase over background levels after 6 h of treatment,
suggesting that peripherally administered IFN-α can enhance
IFN-α signaling in the hippocampus.
As microglia are the primary immune cells that produce proin-
ﬂammatory cytokines in response to inﬂammatory stimuli in
the brain, we examined the activation of microglia in IFN-α-
treated mice by immunostaining for Iba1, a microglial marker
FIGURE 1 | Chronic treatment with minocycline inhibits IFN-α-induced
proinflammatory cytokine expression in the hippocampus. (A)
Time-dependent alteration of IFN-α, IL-1β, IL-6, and TNF-α mRNA levels in
the hippocampus at 2, 6, and 24 h following the ﬁnal IFN-α injection of the
5-week treatment. The mRNAs were quantiﬁed by real-time PCR, and the
results are expressed as relative values, compared to the PBS-treated
control group. n = 3 mice per group. *P < 0.05, **P < 0.01 versus the
PBS-treated group. (B) Experimental design of the minocycline study.
(C–E) Effect of minocycline on IFN-α-induced microglial activation in the
hippocampus. Coronal brain sections prepared after the 5-week treatment
with IFN-α in the presence or absence of minocycline, immunostained for
Iba1, a microglial marker (red) with Hoechst nuclear staining (blue) (C).
Density of Iba1+ microglia in the DG and hilus (D). Relative IFN-α, IL-1β,
IL-6, and TNF-α mRNA levels in the hippocampus quantiﬁed by real-time
PCR (E). n = 5 mice per group. *P < 0.05, **P < 0.01. Error bars:
means ± SEM; Scale bar, 25 μm.
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(Figures 1B–D). In the DG and hilus of the hippocampus, in
contrast to the ramiﬁed microglia in the control PBS-treated
group, which had elongated thin processes extending from a
small soma (Figure 1C, left), microglia in the IFN-α treatment
group exhibited a hypertrophic morphology with a larger soma
and thicker processes (Figure 1C, middle), typical of activated
microglia (Schiepers et al., 2005; Giunti et al., 2014). IFN-α treat-
ment also signiﬁcantly increased the density of Iba1+ microglia
in the hippocampus, including the DG and hilus (Figure 1D) and
CA3 (Supplementary Figure 1A), but not in other brain regions
implicated in the pathology of depression (Belzung et al., 2014;
Figure 1D; Supplementary Figure 1A). These ﬁndings suggested
that the 4-week IFN-α treatment resulted in microglial activation
in the hippocampus.
Minocycline, a tetracycline-type antibiotic with anti-
inﬂammatory properties, readily crosses the blood–brain bar-
rier and suppresses microglial activation (Garrido-Mesa et al.,
2013). To investigate its ability to suppress the IFN-α-induced
microglial activation, minocycline treatment was begun 2 days
before the 5-week IFN-α treatment, and continued for the
duration of the experiment (Figure 1B). The minocycline treat-
ment suppressed both the IFN-α-induced hypertrophic change
in microglial morphology (Figure 1C, right) and the increase
in Iba1+ cell density in the DG and hilus (Figure 1D). More-
over, minocycline treatment signiﬁcantly suppressed the IFN-α-
induced up-regulation of proinﬂammatory cytokine mRNAs in
the hippocampus (Figure 1E). Taken together, these results suggest
that IFN-α increases the expression of endogenous proinﬂamma-
tory cytokines, including IFN-α, via microglial activation in the
hippocampus.
IFN-α-TREATED MICROGLIA SECRETE PROINFLAMMATORY CYTOKINES
AND SUPPRESS PROLIFERATION OF ADULT HIPPOCAMPAL NSCs
To investigate the direct effects of IFN-α on microglia in vitro,
microglia-derived BV-2 cells were treated with IFN-α (1 × 103
IU/ml) for 6 h. After being carefully washed to remove IFN-α, the
cells were cultured in fresh medium without FBS (Figure 2A). To
determine the levels of IFN-α, IL-1β, IL-6, and TNF-α released
from the microglia, culture supernatants were collected at 6,
12, 18, 24, and 48 h after IFN-α removal, and analyzed by
ELISA (Figure 2B). The concentrations of these cytokines were
signiﬁcantly increased at all time points in the IFN-α-treated
group, compared with those in the PBS-treated control group,
indicating that IFN-α stimulates the microglial production of
proinﬂammatory cytokines.
We next examined the effects of the microglial conditioned
medium (CM) on cultured adult hippocampal NSCs. The
microglial CM, collected 24 h after the 6 h treatment with IFN-α
(IFN-CM) or PBS (PBS-CM; Figure 2A), was added to the NSC
cultures, and the cells were incubated for 48 h. During the last
4 h of the incubation, BrdU was added to label the proliferating
NSCs. The percentage of BrdU+ cells in the Nestin+ population
of the IFN-CM-treated culture was signiﬁcantly reduced com-
pared with that in the PBS-CM-treated culture (Figures 2C,D).
These data suggest that secreted factors from the IFN-α-stimulated
microglia suppressed the proliferation of the hippocampal
NSCs.
We recently reported that IFN-α decreases the proliferation of
cultured hippocampal NSCs without affecting their differentia-
tion (Zheng et al., 2014). Therefore, we examined whether the
IFN-α produced by the IFN-α-stimulated microglia was responsi-
ble for suppressing NSC proliferation, by adding a neutralizing
anti-IFN-α antibody (1 μg/ml) to the IFN-CM just before its
incubation with NSCs. The impaired proliferation of NSCs in
response to IFN-CM was signiﬁcantly, although not completely,
restored by the anti-IFN-α antibody (Figure 2D), suggesting that
IFN-α present in the microglial CM played an important role in
suppressing NSC proliferation. Taken together, these results sug-
gest that the in vivo IFN-α treatment promotes the microglial
production and secretion of IFN-α, which suppresses NSC
proliferation.
MINOCYCLINE AMELIORATES IFN-α-INDUCED NEUROGENIC DEFECTS
AND DEPRESSION-LIKE BEHAVIORS
Weﬁnally tested whether the IFN-α-induced defects in hippocam-
pal neurogenesis and induction of depressive behaviors (Zheng
et al., 2014) could be ameliorated by an anti-microglial agent.
Mice were treated with minocycline (50 mg/kg) for 2 d prior to
and during the IFN-α (4 × 105 IU/kg) treatment (Figure 3A).
After the 4-week treatment, brain sections were immunostained
for the proliferation marker Ki67 (Figure 3B) and the neuronal
progenitor marker TBR2 (Figure 3C). To quantify newly gen-
erated neurons, the mice were injected with BrdU once every
8 h for a total of six injections, at the beginning of the 5th
week of the IFN-α/minocycline treatment, and the brain sections
were immunostained for BrdU and DCX, a marker of imma-
ture neurons. The decreased numbers of Ki67+cells (Figure 3D),
TBR2+ cells (Figure 3E), and BrdU+DCX+ cells in the IFN-α-
treated group (Figures 3F,G) were signiﬁcantly restored by the
simultaneous treatment with minocycline.
Interferon-alpha-treated mice exhibit increased immobility in
the tail-suspension (Steru et al., 1985) and forced swimming tests
(Porsolt et al., 1977), typical depression-like behavioral pheno-
types in rodents (Zheng et al., 2014). Simultaneous minocycline
administration signiﬁcantly reduced the observed immobility
times in these tests (Figures 3H,I). Minocycline did not alter neu-
rogenesis or behavior in mice that did not receive the IFN-α treat-
ment (Figures 3D,E,G–I). Taken together, these results suggest
that minocycline treatment ameliorated IFN-α-induced defects in
hippocampal neurogenesis and depression-like behaviors via the
suppression of microglial activation.
DISCUSSION
Depression is a major and serious side effect of IFN-α that lim-
its its use as an antiviral and antitumor drug; however, the
underlying mechanism of IFN-α-induced depression remains
unclear. In this study, we demonstrated that systemic IFN-α treat-
ment caused microglial activation and cytokine production in
the hippocampus. The IFN-α-induced decrease in hippocampal
neurogenesis and increase in depression-like behaviors were sig-
niﬁcantly improved by co-administration of the anti-microglial
agent minocycline. These results suggest that microglia play an
important role in the development of depression during IFN-α
treatment.
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FIGURE 2 | IFN-α-stimulated microglia suppress proliferation of
hippocampal NSCs by production and release of IFN-α. (A) Experimental
design. (B) Proinﬂammatory cytokine levels in the conditioned media (CM) of
microglia following incubation with IFN-α. The CM samples were collected
before (control) or 6, 12, 18, 24, and 48 h after the 6 h incubation with IFN-α.
The concentrations of IFN-α, IL-1β, IL-6, andTNF-α were quantiﬁed by ELISA
and are expressed as relative values compared to the control. n = 6 cultures
per group; Cnt, control. (C,D) Proliferation of the cultured hippocampal NSCs
incubated with the CM from PBS or IFN-α-stimulated microglia (PBS-CM or
IFN-CM, respectively), or with IFN-CM supplemented with an IFN-α
neutralizing antibody (IFN-CM + IFN-α ab). NSCs were immunostained for
Nestin and BrdU (C), then the percentage of BrdU+ cells in the Nestin+
population was quantiﬁed (D). n = 6 cultures per group. *P < 0.05,
**P < 0.01. Error bars: means ± SEM, Scale bar, 20 μm.
Although new neuron production was responsive to IFN-α and
minocycline, the density of NeuN+ mature neurons in the gran-
ule cell layer in the DG was not affected by these treatments,
similar to those in the CA3, amygdala, prefrontal cortex, and
cingulate cortex, non-neurogenic areas implicated in the pathol-
ogy of depression (Hulvershorn et al., 2011; Belzung et al., 2014;
Supplementary Figure 1B). This lack of effect might be due to
the small contribution of new neurons to the neuronal network
in the DG (Ninkovic et al., 2007; Imayoshi et al., 2008). Con-
sistent with this possibility, we did not ﬁnd any differences in
the expression of MAP2, PSD95, or Synaptophysin1, markers of
synaptic plasticity (VanGuilder et al., 2010), in the projection area
of the new neurons (hilus and CA3) among the treatment groups
(Supplementary Figure 1C). Together with our previous ﬁndings
that IFN-α suppresses the proliferation and survival of NSCs,
but not those of differentiated cells (Zheng et al., 2014), these
data support our hypothesis that NSCs are susceptible to IFN-α,
an effect that may play a role in the pathology of IFN-induced
depression.
Microglia are activated by various inﬂammatory stimuli; how-
ever, the effect of IFN-α treatment on these cells has been unclear.
Our in vitro experiments revealed thatmicroglia exposed to IFN-α
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FIGURE 3 | Minocycline treatment ameliorates IFN-α-induced
neurogenic defects and depressive behaviors. (A) Experimental design.
(B–E) Quantiﬁcation of proliferating cells in the SGZ following the 4-week
treatment with PBS or IFN-α, in the absence or presence of minocycline
(Mino). The brain sections were immunostained for the proliferation marker,
Ki67 (B) and neuronal progenitor marker, TBR2 (C), and then the Ki67+ and
TBR2+ cells in the SGZ were counted and compared among the treatment
groups (Ki67, D; TBR2, E). n = 7 mice per group. (F,G) Quantiﬁcation of
newly generated neurons in the DG after the 5-week IFN-α treatment. The
new neurons were labeled with BrdU administered at the beginning at the
5th week of the IFN-α treatment and visualized by immunostaining for
BrdU and DCX, a marker of immature neurons (F) The number of
BrdU+DCX+ cells in the DG was counted and compared among the
groups. n = 5 mice per group. (H,I) The effects of IFN-α and minocycline
on depression-like behaviors in mice. After the ﬁnal injection of IFN-α
and/or minocycline, the mice were subjected to the tail suspension (H) and
forced swimming test (I). The immobility times observed in these tests
were quantiﬁed and compared among the groups. n = 10 mice per
group. *P < 0.05; **P < 0.01; Error bars: means ± SEM; Scale bars:
(B,C) = 100 μm; (F) = 25 μm.
exhibited increasedproinﬂammatory cytokine release (Figure 2B),
suggesting that IFN-α can directly activate microglia. Interest-
ingly, the density of microglia in the hippocampus, but not in
other regions implicated in the pathology of depression (Hulver-
shorn et al., 2011; Belzung et al., 2014), was signiﬁcantly increased
(Figure 1D; Supplementary Figure 1A). These data suggest that
microglia in the hippocampus are more sensitive to IFN-α than
the microglia in other brain regions. It is also possible that the
hippocampal microglia were exposed to a higher concentration
of IFN-α due to their location close to the ventricle, although
the precise pharmacological kinetics of IFN-α in the brain is
unknown. Previous studies indicate that microglia have diverse
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context-dependent effects on NSCs (Garden and Moller, 2006;
Gonzalez-Perez et al., 2012; Gemma and Bachstetter, 2013). They
modulate the proliferation, survival, and neuronal differentiation
of NSCs and their progeny by releasing cytokines (Aarum et al.,
2003; Monje et al., 2003; Butovsky et al., 2006; Iosif et al., 2006;
Choi et al., 2008; Vukovic et al., 2012; Shigemoto-Mogami et al.,
2014), and remove apoptotic cells by phagocytosis (Sierra et al.,
2010). Here we found that the CM of IFN-α-stimulated microglia
reduced the proliferation of cultured hippocampal NSCs. Notably,
this effect was signiﬁcantly suppressed in the presence of an IFN-α
neutralizing antibody (Figure 2D). Considering that IFN-α
inhibitsNSCproliferation (Zheng et al., 2014), it is likely that the in
vivo administration of IFN-α inducesmicroglial IFN-α expression,
which suppresses NSC proliferation.
We recently reported that the IFN-α-induced decrease in
hippocampal neurogenesis and depressive behavior was medi-
ated by IFNAR expressed in Nestin+ NSCs and their progeny
(Zheng et al., 2014). In addition to a small fraction of peripheral
IFN-α that enters the brain (Vitkovic et al., 2000), it is pos-
sible that the activation of IFNAR signaling in NSCs involves
endogenous IFN-α expressed in the brain. In IFN-α treated
patients, elevated plasma concentrations of proinﬂammatory
cytokines such as IL-1β, IL-6, and TNF-α were correlated with
the induction of depressive symptoms (Bonaccorso et al., 2001;
Raison et al., 2009, 2010). If these cytokines or other proin-
ﬂammatory factors/cells reach the hippocampus, they may also
cause microglial activation. Thus, hippocampal inﬂammation
may be involved in mediating microglial activation induced by
peripherally administered IFN-α, resulting in the induction of
depression.
Minocycline is a tetracycline derivative that has powerful
anti-inﬂammatory, anti-apoptotic, and antioxidant properties
that are independent of its antibacterial activity. Because of
its high lipid solubility, minocycline easily crosses the blood–
brain barrier (Brogden et al., 1975), where it efﬁciently sup-
presses microglial activation and protects neurons and glial
cells in various brain disease models in which the inﬂamma-
tory process has been implicated, including ischemic stroke,
traumatic injury, and neurodegenerative diseases (Plane et al.,
2010; Garrido-Mesa et al., 2013). Minocycline treatment also
improves depression-like behaviors in animals and depressive
symptoms in patients (Kim and Suh, 2009; Soczynska et al.,
2012), although the underlying molecular and cellular mecha-
nisms by which minocycline functions remain largely unknown.
Here, we demonstrated that minocycline signiﬁcantly improved
IFN-α-induced depression-like behaviors while concomitantly
suppressingmicroglial activation and restoring hippocampal neu-
rogenesis (Figure 3). Minocycline treatment has been reported
to protect NSCs, neuronal progenitors, and new neurons, result-
ing in increased neurogenesis in the hippocampus (Ekdahl et al.,
2003; Liu et al., 2007). Therefore, minocycline treatment can pro-
mote neurogenesis both directly by impacting NSCs and their
progeny, and indirectly via microglial suppression. As reduced
hippocampal neurogenesis is thought to be involved in the
neuropathology of depression, minocycline’s antidepressant-like
action in the IFN-α-treated mice may be due to its ability to
promote neurogenesis.
In conclusion, the results of our study implicate a microglia-
mediated mechanism in the development of IFN-induced depres-
sion. Further studies are needed to determine the precise
mechanism by which minocycline improves depressive behavior.
Although treatment with antidepressants, including the selective
serotonin reuptake inhibitors (SSRIs) can reduce the develop-
ment and symptomsof IFN-induceddepression (Musselmanet al.,
2001; Capuron et al., 2002; Hauser et al., 2002; Raison et al., 2007;
McNutt et al., 2012), some patients are refractory to the conven-
tional antidepressant treatment. Ourdata suggest thatminocycline
may be a promising drug for the treatment of these patients.
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